A Phase 2 interventional study of Ziltivekimab and Placebo (ziltivekimab) in Chronic Kidney Disease, Inflammation and Cardiovascular Risk, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Novo Nordisk A/S.
Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 2, and was the 10th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →5 of the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in China
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 11 more countries
Ages 18+
Novo Nordisk A/S · Sites in Korea, Republic of
Ages 19+
Novo Nordisk A/S · Sites in United States, Brazil, China and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18–75
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 128 across the 18 interventional studies, 1,500 across the 11 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
1 of the studies in Renal Insufficiency, Chronic by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07808788Novo Nordisk A/SA Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney Function | 2027-07-06 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to compare the safety and effectiveness of 2 different doses of a study drug called ziltivekimab to placebo (an inactive substance) in reducing inflammation and improving some of the bad effects of inflammation on heart disease. Participants will be randomly (by chance) assigned to receive either ziltivekimab or placebo. The chance that participants will be assigned into one of the three study arms of ziltivekimab (either 15 mg or 30 mg) or placebo is the same (approximately 33%). This is a double-blind study, which means neither participants nor the study doctor will know which group the participants are in. In case of an emergency, however, the study doctor can get this information. The study drug will be injected under the skin once every 4 weeks. In this study participants will receive 3 injections of study drug. The total study duration for each participant will be approximately 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The patient agrees to comply with the and reproduction restrictions of the study as follows:
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from participation in the study:
Laboratory values
Medical conditions or diseases
Prior or current medications
General exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ziltivekimab 15 mg for 12 weeks.
Drug: Ziltivekimab
Participants will receive ziltivekimab 30 mg for 12 weeks.
Drug: Ziltivekimab
Participants will receive placebo (ziltivekimab) for 12 weeks.
Drug: Placebo (ziltivekimab)
Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks
Administered s.c. once every 4 weeks for 12 weeks
Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) Levels From Baseline (Average of All Hs-CRP Values Prior to the Administration of Study Drug) to the End of Treatment (Average of Week 10 and Week 12)
Percent change in hs-CRP levels from baseline (average of the hs-CRP value prior to the administration of study drug) to the end of treatment (average of Week 10 and Week 12) is presented. Baseline was defined as the average of all hs-CRP values prior to the first administration of study drug at day 1 and end of treatment was defined as the average of hs-CRP values at week 10 and week 12.
Time frame: Baseline (day 1), end of treatment (average of week 10 and week 12)
Number of Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any undesirable event or any untoward medical occurrence that occurred in a participant during the course of the study or the protocol-defined time after study termination, whether or not that event was considered study drug-related. A TEAE was defined as an AE that initiated or worsened on or after the date of first dose of study drug up to the end of the safety follow-up period (week 20). Number of TEAEs from randomization (day 1) to week 20 are presented.
Time frame: From randomization (Day 1) to week 20
Number of Serious Adverse Events (SAEs)
An AE was any undesirable event or any untoward medical occurrence that occurred in a participant during the course of the study or the protocol-defined time after study termination, whether or not that event was considered study drug-related. An SAE was defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. ). Number of SAEs from randomization (day 1) to week 20 are presented.
Time frame: From randomization (Day 1) to week 20
Number of Participants With Vital Signs Parameters Exceeding Pre-defined Criteria
Number of participants with vital signs parameters (including systolic blood pressure, heart rate and respiratory rate) exceeding pre-defined criteria are presented. The pre-defined criteria were: 1) systolic blood pressure: greater than (\>25) millimeters of mercury (mmHg) increase or decrease from baseline and \>160 mmHg; 2) heart rate: \>100 beats per minute; 3)respiratory rate: \>24 breaths per minute.
Time frame: From randomization (Day 1) to week 20
Change in Electrocardiogram (ECG)
The ECG was assessed by the investigator at baseline (Day 1) and week 20 and categorised as abnormal clinically significant, abnormal not clinically significant, indeterminate, normal, not evaluable and unknown. Number of participants in each ECG category at baseline and week 20 are presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Aspartate Aminotransferase, Creatine Kinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase (LDH) and Lipase Pancreatic
Change from baseline (Day 1) to week 20 in alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, creatine kinase, gamma glutamyl transferase, LDH and lipase pancreatic is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Bicarbonate, Chloride, Potassium and Sodium
Change from baseline (Day 1) to Week 20 in bicarbonate, chloride, potassium and sodium is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Phosphate, Urate, Urea Nitrogen
Change from baseline (Day 1) to week 20 in bilirubin, calcium, creatinine, direct bilirubin, glucose, phosphate, urate and urea nitrogen is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Glomerular Filtration Rate
Change from baseline (Day 1) to week 20 in glomerular filtration rate is presented. Glomerular filtration rate was calculated by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)creatinine equation.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Protein
Change from baseline (Day 1) to week 20 in protein is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Eosinophils, Leukocyctes, Lymphocytes, Monocytes, Neutrophils and Platelets
Change from baseline (Day 1) to week 20 in eosinophils, leukocyctes, lymphocytes, monocytes, neutrophils and platelets is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Eosinophil/Leukocytes
Change from baseline (Day 1) to week 20 in eosinophil/leukocytes is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Erythrocyte Mean Corpuscular Volume
Change from baseline (Day 1) to week 20 in erythrocyte mean corpuscular volume is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Erythrocytes
Change from baseline (Day 1) to week 20 in erythrocytes is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Erythrocyte Distribution Width
Change from baseline (Day 1) to week 20 in erythrocyte distribution width (ery. distribution width) is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Hematocrit
Change from baseline (Day 1) to week 20 in hematocrit is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Lymphocytes/Leukocytes
Change from baseline (Day 1) to week 20 in lymphocytes/leukocytes is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Monocytes/Leukocytes
Change from baseline (Day 1) to week 20 in monocytes/leukocytes is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Neutrophils/Leukocytes
Change from baseline (Day 1) to week 20 in neutrophils/leukocytes is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Reticulocytes/Erythrocytes
Change from baseline (Day 1) to week 20 in reticulocytes/erythrocytes is presented.
Time frame: Baseline (Day 1), Week 20
Change From Baseline in Protein Creatinine Ratio
Change from baseline (Day 1) to week 12 in protein creatinine ratio is presented.
Time frame: Baseline (Day 1), Week 12
Change From Baseline in Specific Gravity of Urine
Change from baseline (Day 1) to week 12 in specific gravity of urine is presented.
Time frame: Baseline (Day 1), Week 12
Change From Baseline in Spot Urine Albumin, Spot Urine Creatinine, Spot Urine Protein and Urobilinogen
Change from baseline (Day 1) to week 12 in spot urine albumin, spot urine creatinine, spot urine protein and urobilinogen is presented.
Time frame: Baseline (Day 1), Week 12
Change From Baseline in Urine pH
Change from baseline (Day 1) to week 12 in urine pH is presented.
Time frame: Baseline (Day 1), Week 12
Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Drug
Percentage of participants with AEs leading to discontinuation of study drug is presented.
Time frame: From randomization (Day 1) to week 20
Number of Treatment Emergent Adverse Events of Special Interest (AESIs)
AESIs included serious infection, Common Terminology Criteria for Adverse Events (CTCAE) Grade greater than or equal to (\>=) 3 injection-related reactions, gastrointestinal perforations, CTCAE Grade \>=3 anaphylaxis that occurred at any time, even if considered unrelated to the study drug, neutrophil less than (\<) 500/mm\^3 (CTCAE Grade 4) or neutrophil \<1000/mm\^3 (CTCAE Grade 3) with evidence of concurrent infection, thrombocytopenia (platelet count \<50,000/mm\^3 \[CTCAE Grade 3\]) or platelet count \<75,000/mm\^3 (CTCAE Grade 2) with evidence of concurrent major bleeding and malignancies. Number of treatment emergent adverse events of special interest (AESIs) is presented.
Time frame: From randomization (Day 1) to week 20
Number of Participants With Antidrug Antibodies (ADAs) to Ziltivekimab
Number of participants with ADAs to Ziltivekimab is presented. Data presented is partcipants who had at least 1 positive antibody sample (treatment-boosted or treatment-induced) at any time after their first Ziltivekimab administration.
Time frame: From randomization (Day 1) to week 20
The trial was conducted in Japan and included 12 sites that were initiated, 11 sites that screened study participants, and 10 sites that enrolled study participants.
| Milestone | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Started | 13 | 11 | 12 |
| Treated | 12 | 11 | 12 |
| Intent-to-treat (itt) population | 13 | 11 | 12 |
| Safety population | 12 | 11 | 12 |
| Completed | 12 | 11 | 12 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
Percent change in hs-CRP levels from baseline (average of the hs-CRP value prior to the administration of study drug) to the end of treatment (average of Week 10 and Week 12) is presented. Baseline was defined as the average of all hs-CRP values prior to the first administration of study drug at day 1 and end of treatment was defined as the average of hs-CRP values at week 10 and week 12.
| Percent change | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) Levels From Baseline (Average of All Hs-CRP Values Prior to the Administration of Study Drug) to the End of Treatment (Average of Week 10 and Week 12) | -27.01 (-46.71 to -3.83) | -96.23 (-98.89 to -91.67) | -93.41 (-96.59 to -88.34) |
An adverse event (AE) was any undesirable event or any untoward medical occurrence that occurred in a participant during the course of the study or the protocol-defined time after study termination, whether or not that event was considered study drug-related. A TEAE was defined as an AE that initiated or worsened on or after the date of first dose of study drug up to the end of the safety follow-up period (week 20). Number of TEAEs from randomization (day 1) to week 20 are presented.
| Events | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Number of Treatment-emergent Adverse Events (TEAEs) | 25 | 41 | 16 |
An AE was any undesirable event or any untoward medical occurrence that occurred in a participant during the course of the study or the protocol-defined time after study termination, whether or not that event was considered study drug-related. An SAE was defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. ). Number of SAEs from randomization (day 1) to week 20 are presented.
| Events | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Number of Serious Adverse Events (SAEs) | 2 | 5 | 0 |
Number of participants with vital signs parameters (including systolic blood pressure, heart rate and respiratory rate) exceeding pre-defined criteria are presented. The pre-defined criteria were: 1) systolic blood pressure: greater than (\>25) millimeters of mercury (mmHg) increase or decrease from baseline and \>160 mmHg; 2) heart rate: \>100 beats per minute; 3)respiratory rate: \>24 breaths per minute.
| Participants | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Systolic Blood Pressure: >25 mmHg increase or decrease from baseline | 5 | 3 | 4 |
| Systolic Blood Pressure: >160 mmHg | 2 | 2 | 0 |
| Heart Rate: >100 beats per minute | 1 | 2 | 0 |
| Respiratory Rate: >24 breaths per minute | 0 | 0 | 0 |
The ECG was assessed by the investigator at baseline (Day 1) and week 20 and categorised as abnormal clinically significant, abnormal not clinically significant, indeterminate, normal, not evaluable and unknown. Number of participants in each ECG category at baseline and week 20 are presented.
| Participants | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Baseline (Day 1) — Abnormal, clinically significant | 0 | 2 | 1 |
| Baseline (Day 1) — Abnormal, not clinically significant | 5 | 2 | 1 |
| Baseline (Day 1) — Indeterminate | 0 | 0 | 0 |
| Baseline (Day 1) — Normal | 7 | 7 | 10 |
| Baseline (Day 1) — Not evaluable | 0 | 0 | 0 |
| Baseline (Day 1) — Unknown | 0 | 0 | 0 |
| Week 20 — Abnormal, clinically significant | 1 | 1 | 0 |
| Week 20 — Abnormal, not clinically significant | 5 | 3 | 2 |
| Week 20 — Indeterminate | 0 | 0 | 0 |
| Week 20 — Normal | 6 | 7 | 10 |
| Week 20 — Not evaluable | 0 | 0 | 0 |
| Week 20 — Unknown | 0 | 0 | 0 |
Change from baseline (Day 1) to week 20 in alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, creatine kinase, gamma glutamyl transferase, LDH and lipase pancreatic is presented.
| Units per liter (U/L) | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Alanine Aminotransferase | 3.9 ± 13.96 | 21.9 ± 34.61 | 5.6 ± 6.32 |
| Alkaline Phosphatase | 0.4 ± 8.64 | -6.2 ± 18.14 | -12.4 ± 14.43 |
| Amylase | 2.3 ± 13.37 | 6.7 ± 24.60 | 2.3 ± 18.19 |
| Aspartate Aminotransferase | -0.6 ± 9.84 | 11.5 ± 14.17 | 0.7 ± 5.14 |
| Creatine Kinase | -36.2 ± 64.57 | 19.9 ± 49.88 | 3.2 ± 38.00 |
| Gamma Glutamyl Transferase | 0.4 ± 8.03 | 7.0 ± 11.37 | 5.8 ± 5.19 |
| LDH | 2.5 ± 15.71 | 19.5 ± 28.24 | 15.9 ± 15.26 |
| Lipase, Pancreatic | 15.9 ± 22.74 | 27.9 ± 40.90 | 6.8 ± 41.20 |
Change from baseline (Day 1) to Week 20 in bicarbonate, chloride, potassium and sodium is presented.
| millimoles/L (mmol/L) | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Bicarbonate | -0.4 ± 3.73 | -1.7 ± 2.00 | -1.6 ± 2.68 |
| Chloride | 0.8 ± 2.73 | 1.1 ± 2.21 | 1.3 ± 3.44 |
| Potassium | -0.38 ± 0.501 | -0.30 ± 0.650 | 0.15 ± 0.284 |
| Sodium | 0.7 ± 3.26 | 0.1 ± 2.47 | 0.0 ± 3.62 |
Change from baseline (Day 1) to week 20 in bilirubin, calcium, creatinine, direct bilirubin, glucose, phosphate, urate and urea nitrogen is presented.
| milligrams/deciliter (mg/dL) | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Bilirubin | -0.122 ± 0.1497 | 0.158 ± 0.3073 | 0.030 ± 0.1566 |
| Calcium | -0.10 ± 0.429 | -0.17 ± 0.413 | 0.08 ± 0.357 |
| Creatinine | 0.176 ± 0.2087 | 0.188 ± 0.2368 | 0.210 ± 0.2895 |
| Direct bilirubin | -0.019 ± 0.0198 | 0.039 ± 0.0973 | 0.007 ± 0.0350 |
| Glucose | 13.4 ± 45.58 | 15.9 ± 21.64 | 1.7 ± 14.84 |
| Phosphate | -0.13 ± 0.408 | 0.22 ± 0.374 | 0.29 ± 0.287 |
| Urate | 0.27 ± 1.113 | 0.47 ± 1.084 | 0.06 ± 0.611 |
| Urea nitrogen | 3.3 ± 11.87 | 5.5 ± 8.23 | 6.3 ± 7.76 |
Change from baseline (Day 1) to week 20 in glomerular filtration rate is presented. Glomerular filtration rate was calculated by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)creatinine equation.
| mL/min/1.73m^2 | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Glomerular Filtration Rate | -3.9 ± 5.90 | -3.5 ± 3.98 | -3.8 ± 3.02 |
Change from baseline (Day 1) to week 20 in protein is presented.
| grams per deciliter (g/dL) | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Protein | -0.02 ± 0.296 | -0.49 ± 0.617 | -0.02 ± 0.397 |
Change from baseline (Day 1) to week 20 in eosinophils, leukocyctes, lymphocytes, monocytes, neutrophils and platelets is presented.
| cells*10^9/L | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Eosinophils | 0.02 ± 0.083 | -0.05 ± 0.288 | 0.08 ± 0.134 |
| Leukocyctes | 0.44 ± 1.394 | -0.96 ± 1.615 | -0.73 ± 1.150 |
| Lymphocytes | 0.288 ± 0.4916 | -0.047 ± 0.4840 | 0.066 ± 0.3977 |
| Monocytes | 0.07 ± 0.277 | 0.11 ± 0.187 | 0.01 ± 0.183 |
| Neutrophils | 0.062 ± 1.0308 | -0.974 ± 1.4803 | -0.900 ± 1.3441 |
| Platelets | -0.1 ± 46.23 | -35.7 ± 22.10 | -39.6 ± 35.56 |
Change from baseline (Day 1) to week 20 in eosinophil/leukocytes is presented.
| Percentage of eosinophil/leukocytes | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Eosinophil/Leukocytes | 0.24 ± 1.150 | -0.38 ± 3.828 | 1.43 ± 1.966 |
Change from baseline (Day 1) to week 20 in erythrocyte mean corpuscular volume is presented.
| femtoliters (fL) | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Erythrocyte Mean Corpuscular Volume | 0.18 ± 1.207 | 2.44 ± 2.368 | 2.92 ± 1.243 |
Change from baseline (Day 1) to week 20 in erythrocytes is presented.
| cells x 10^12/L | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Erythrocytes | -0.037 ± 0.2324 | -0.113 ± 0.2376 | -0.095 ± 0.1951 |
Change from baseline (Day 1) to week 20 in erythrocyte distribution width (ery. distribution width) is presented.
| Percentage of ery. distribution width | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Erythrocyte Distribution Width | 0.42 ± 0.575 | -0.15 ± 0.747 | 0.22 ± 0.658 |
Change from baseline (Day 1) to week 20 in hematocrit is presented.
| Percentage of hematocrit | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Hematocrit | -0.3 ± 2.22 | -0.1 ± 2.39 | 0.3 ± 2.05 |
Change from baseline (Day 1) to week 20 in lymphocytes/leukocytes is presented.
| Percentage of lymphocytes/leukocytes | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Lymphocytes/Leukocytes | 3.07 ± 4.980 | 1.76 ± 5.710 | 4.62 ± 6.592 |
Change from baseline (Day 1) to week 20 in monocytes/leukocytes is presented.
| Percentage of monocytes/leukocytes | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Monocytes/Leukocytes | 0.50 ± 3.108 | 2.05 ± 2.508 | 0.71 ± 2.831 |
Change from baseline (Day 1) to week 20 in neutrophils/leukocytes is presented.
| Percentage of neutrophils/leukocytes | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Neutrophils/Leukocytes | -3.82 ± 6.593 | -3.32 ± 6.201 | -6.76 ± 9.278 |
Change from baseline (Day 1) to week 20 in reticulocytes/erythrocytes is presented.
| Percentage of reticulocytes/erythrocytes | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Reticulocytes/Erythrocytes | 0.11 ± 0.847 | -0.02 ± 0.389 | -0.04 ± 0.345 |
Change from baseline (Day 1) to week 12 in protein creatinine ratio is presented.
| grams per kilogram (g/kg) | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Protein Creatinine Ratio | 412.3 ± 1783.53 | -148.9 ± 830.30 | -382.3 ± 729.52 |
Change from baseline (Day 1) to week 12 in specific gravity of urine is presented.
| Ratio | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Specific Gravity of Urine | 0.0013 ± 0.00341 | -0.0009 ± 0.00263 | -0.0002 ± 0.00558 |
Change from baseline (Day 1) to week 12 in spot urine albumin, spot urine creatinine, spot urine protein and urobilinogen is presented.
| milligrams/deciliter (mg/dL) | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Spot urine albumin | 48.863 ± 132.0202 | 28.103 ± 94.3076 | -25.408 ± 36.3713 |
| Spot urine creatinine | 7.48 ± 31.854 | 10.95 ± 43.490 | 0.34 ± 51.873 |
| Spot urine protein | 51.7 ± 162.06 | 38.8 ± 132.45 | -61.7 ± 92.90 |
| Urobilinogen | 0.07 ± 0.231 | 0.00 ± 0.000 | -0.13 ± 0.311 |
Change from baseline (Day 1) to week 12 in urine pH is presented.
| pH | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Change From Baseline in Urine pH | 0.21 ± 0.450 | 0.23 ± 0.467 | 0.13 ± 0.433 |
Percentage of participants with AEs leading to discontinuation of study drug is presented.
| Percentage of participants | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Drug | 0 | 0 | 0 |
AESIs included serious infection, Common Terminology Criteria for Adverse Events (CTCAE) Grade greater than or equal to (\>=) 3 injection-related reactions, gastrointestinal perforations, CTCAE Grade \>=3 anaphylaxis that occurred at any time, even if considered unrelated to the study drug, neutrophil less than (\<) 500/mm\^3 (CTCAE Grade 4) or neutrophil \<1000/mm\^3 (CTCAE Grade 3) with evidence of concurrent infection, thrombocytopenia (platelet count \<50,000/mm\^3 \[CTCAE Grade 3\]) or platelet count \<75,000/mm\^3 (CTCAE Grade 2) with evidence of concurrent major bleeding and malignancies. Number of treatment emergent adverse events of special interest (AESIs) is presented.
| Events | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Number of Treatment Emergent Adverse Events of Special Interest (AESIs) | 1 | 1 | 0 |
Number of participants with ADAs to Ziltivekimab is presented. Data presented is partcipants who had at least 1 positive antibody sample (treatment-boosted or treatment-induced) at any time after their first Ziltivekimab administration.
| Participants | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|
| Number of Participants With Antidrug Antibodies (ADAs) to Ziltivekimab | 0 | 0 |
Collected over From randomization (Day 1) to week 20. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/12 (0%) | 2/12 (16.7%) | 7/12 (58.3%) |
| Ziltivekimab 15 mg | 0/11 (0%) | 2/11 (18.2%) | 10/11 (90.9%) |
| Ziltivekimab 30 mg | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Event | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Angina unstableCardiac disorders | 0/12 | 1/11 | 0/12 |
| AppendicitisInfections and infestations | 0/12 | 1/11 | 0/12 |
| Cardiac failure acuteCardiac disorders | 0/12 | 1/11 | 0/12 |
| Chronic kidney diseaseRenal and urinary disorders | 0/12 | 1/11 | 0/12 |
| Impaired healingGeneral disorders | 0/12 | 1/11 | 0/12 |
| Corona virus infectionInfections and infestations | 1/12 | 0/11 | 0/12 |
| Nephrotic syndromeRenal and urinary disorders | 1/12 | 0/11 | 0/12 |
| Event | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg |
|---|---|---|---|
| Blood bilirubin increasedInvestigations | 0/12 | 2/11 | 0/12 |
| EosinophiliaBlood and lymphatic system disorders | 0/12 | 2/11 | 0/12 |
| PeriodontitisInfections and infestations | 2/12 | 1/11 | 1/12 |
| Administration site pruritusGeneral disorders | 0/12 | 1/11 | 0/12 |
| Atrial flutterCardiac disorders | 0/12 | 1/11 | 0/12 |
| Blood pressure increasedInvestigations | 0/12 | 1/11 | 0/12 |
| Cardiac failureCardiac disorders | 0/12 | 1/11 | 0/12 |
| Cardiac failure chronicCardiac disorders | 0/12 | 1/11 | 0/12 |
| ConjunctivitisInfections and infestations | 0/12 | 1/11 | 0/12 |
| ConstipationGastrointestinal disorders | 0/12 | 1/11 | 1/12 |
Intent-to-Treat (ITT) population included all randomized participants.
| Age, Continuous(Years) | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg | Total |
|---|---|---|---|---|
| Mean | 63.6 ± 12.01 | 66.2 ± 10.26 | 61.4 ± 15.09 | 63.7 ± 12.44 |
| Sex: Female, Male(Participants) | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg | Total |
|---|---|---|---|---|
| Female | 5 | 4 | 3 | 12 |
| Male | 8 | 7 | 9 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 13 | 11 | 12 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Ziltivekimab 15 mg | Ziltivekimab 30 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 13 | 11 | 12 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Oct 2020 to primary completion in Aug 2021, 9 months.
Results were first posted in May 2026, 4 years 9 months after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 9 months is below that.
Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ziltivekimab
Renal Insufficiency, Chronic →